【摘要】 目的 探讨利妥昔单抗联合苯达莫司汀治疗晚期套细胞淋巴瘤的效果。方法 将信阳市中心医院2020年10月至2022年10月收治的82例晚期套细胞淋巴瘤患者按随机数字表法分为观察组和常规组，各41例。常规组接受苯利妥昔单抗治疗，观察组接受苯利妥昔单抗联合苯达莫司汀。比较两组患者卡氏评分、临床疗效、血清血管内皮生长因子(VEGF)水平、药物不良反应。结果 治疗4周后，观察组卡氏评分高于常规组，VEGF水平低于常规组(P<0.05)。观察组的客观缓解率高于常规组，不良反应发生率低于常规组(P<0.05)。结论 利妥昔单抗联合苯达莫司汀治疗晚期套细胞淋巴瘤患者能够改善临床症状，效果确切，同时可以降低血清VEGF水平，降低患者的不良反应发生率，值得推广与应用。更多还原

【Abstract】 Objective To investigate the efficacy of rituximab combined with bendamustine in the treatment of advanced mantle cell lymphoma.Methods A total of 82 patients with advanced mantle cell lymphoma admitted to Xinyang Central Hospital from October 2020 to October 2022 were divided into observation group and conventional group according to the random number table method, with 41 cases in each group. The conventional group received phenelztuximab treatment, and the observation group received phenelztuximab combined with bendamustine. The two groups of patients with Kahn’s score, clinical efficacy, serum vascular endothelial growth factor(VEGF) levels and adverse drug reactions were compared.Results The Kahn’s score of the observation group after 4 weeks of treatment was higher than that of the conventional group, and the level of VEGF was lower than that of the conventional group(P<0.05). The objective remission rate of the observation group was higher than that of the conventional group, and the incidence of adverse reactions was lower than that of the conventional group(P<0.05).Conclusion Rituximab combined with bendamustine in the treatment of advanced mantle cell lymphoma can improve clinical symptoms with definite efficacy, and can reduce the level of serum VEGF and the incidence of adverse reactions in patients, which is worthy of promotion and application.更多还原